9 trials changed in the last 30 days: 1 stopped, 5 with notable changes, 3 with minor changes only.
Trial terminated
Also in this update: Study completion date changed from estimate of Aug 19, 2027 to Sep 22, 2026
Children's Oncology GroupPhase 2/3 NCT06820957 Registry history of NCT06820957 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 30, 2026 to Jun 30, 2027
Children's Oncology GroupNot specified NCT06054295 Registry history of NCT06054295 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Children's Oncology GroupPhase 2 NCT04195399 Registry history of NCT04195399 on ClinicalTrials.gov (opens the registry)
Phase changed: not applicable → Phase 2
Also in this update: Trial sites expanded: 5 → 13 locations
Children's Oncology GroupPhase 2 NCT07621614 Registry history of NCT07621614 on ClinicalTrials.gov (opens the registry)
Sponsor changed: National Cancer Institute (NCI) to Children's Oncology Group
Also in this update: Study completion pushed from Oct 16, 2026 to Aug 20, 2027
Children's Oncology GroupPhase 2 NCT03581292 Registry history of NCT03581292 on ClinicalTrials.gov (opens the registry)
Enrollment reopened
Children's Oncology GroupNot specified NCT00736749 Registry history of NCT00736749 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 29 → 33 locations
Children's Oncology GroupPhase 3 NCT05711667 Registry history of NCT05711667 on ClinicalTrials.gov (opens the registry)
Final enrollment: 391 participants (planned 621)
Also in this update: Study completion pushed from Sep 30, 2026 to Oct 6, 2027; Interventions modified
Children's Oncology GroupPhase 3 NCT02176967 Registry history of NCT02176967 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 14, 2027 to Sep 30, 2034
Children's Oncology GroupPhase 3 NCT03007147 Registry history of NCT03007147 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-30 | NCT07848568 Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA)… | Phase 1/2 | Not Yet Recruiting |
| 2026-09-21 | NCT07830667 A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors… | Phase 1/2 | Not Yet Recruiting |
| Phase 1 | 5 | |
| Phase 1/2 | 6 | |
| Phase 2 | 16 | |
| Phase 2/3 | 1 | |
| Phase 3 | 24 |
Leukemia (24) · Acute Lymphoblastic Leukemia (ALL) (11) · Sarcoma (11) · Acute Myeloid Leukemia (AML) (9) · Glioma (8) · Glioblastoma (3) · Kidney Cancer (3) · Myelodysplastic Syndromes (MDS) (3) · Chronic Myeloid Leukemia (CML) (2) · Hodgkin Lymphoma (2)